Last reviewed · How we verify
Control group(autologous ICBG) — Competitive Intelligence Brief
marketed
Orthopedic Surgery / Bone Regeneration
Small molecule
Live · refreshed every 30 min
Target snapshot
Control group(autologous ICBG) (Control group(autologous ICBG)) — The University of Texas Health Science Center, Houston. Autologous iliac crest bone graft (ICBG) provides structural support and biological factors to promote bone healing and regeneration at the graft site.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Control group(autologous ICBG) TARGET | Control group(autologous ICBG) | The University of Texas Health Science Center, Houston | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Control group(autologous ICBG) CI watch — RSS
- Control group(autologous ICBG) CI watch — Atom
- Control group(autologous ICBG) CI watch — JSON
- Control group(autologous ICBG) alone — RSS
Cite this brief
Drug Landscape (2026). Control group(autologous ICBG) — Competitive Intelligence Brief. https://druglandscape.com/ci/control-group-autologous-icbg. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab